Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PENELOPE-B palbociclib adjuvant trial in high-risk HR-positive/HER2-negative primary breast cancer
2013-001040-62Phase 3Completed
- Sponsor
- GBG Forschungs
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Palbociclib plus standard adjuvant endocrine therapy with Placebo plus standard adjuvant endocrine therapy (2 arms). Primary endpoint: Invasive disease-free survival. Started May 2013; status: completed.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2013-001040-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001040-62.